1.	Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SBG-2-03, EudraCT-number: 2008-002340-42, NCT00790322
2.	Effect of SBG in Patients With Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SBG-2-01, NCT00533364
3.	Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment Phase: Phase II Type: Treatment Status: Completed Age: Any age Sponsor: NCI, Other Protocol IDs: 04-050, MSKCC-04050, NCT00089258
4.	Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma Phase: Phase I Type: Treatment Status: Completed Age: Under 50 Sponsor: NCI, Other Protocol IDs: 01-075, P30CA008748, MSKCC-01075, NCI-G02-2067, NCT00037011
5.	Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Any age Sponsor: NCI, Other Protocol IDs: 05-073, MSKCC-05073, NCT00492167
6.	Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SBG-2-02, NCT00533728
7.	Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis Phase: No phase specified Type: Diagnostic Status: Completed Age: 1 and over Sponsor: NCI Protocol IDs: 090109, 09-C-0109, NCT00923832